Danish Medicines Council makes five recommendations after April meeting

The council has processed five drug applications at this month’s meeting, including proposals from Bristol Meyers Squibb and Novartis, which received thumbs-up for treatments for cancer and spinal arthritis, respectively. Sanofi’s application was rejected and Merck/Pfizer’s combination pitch was not approved, despite new data.

Photo: Stine Rasmussen/Ritzau Scanpix

Wednesday brought bad news for pharmaceutical firms Merck, Pfizer and Sanofi.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs